Objective: To investigate the efficacy and safety of telmisartan 80 mg/amlodipine 5 mg (T80/A5) single-pill combination versus A5 in patients with essential hypertension not adequately controlled on A5 monotherapy. Methods: Asian patients !18 years old, with inadequately controlled blood pressure (BP) at enrolment, who failed to achieve a seated diastolic BP (DBP) goal (!90 mmHg) following 6-weeks' open-label A5 treatment, were randomly allocated 1 : 1 to 8 weeks' double-blind treatment with T80/A5 single-pill combination or A5. Results: A total of 324 patients entered the double-blind treatment phase. The adjusted mean AE SE reduction in seated trough DBP from baseline to week 8 was significantly greater with T80/A5 (12.4 AE 1.0 mmHg) than A5 (10.2 AE 0.9 mmHg [primary endpoint, n ¼ 314]). Results were similar in the subset of 262 Chinese patients. Treatment-related adverse events were 1.9% with T80/A5 and 2.4% with A5. Conclusions: In Asian patients with hypertension, T80/A5 single-pill combination provided improved BP reduction after 8 weeks' treatment compared with A5 monotherapy. Both treatments were well tolerated.
Introduction
In the Asia Pacific region, the prevalence of hypertension ranges between 5% and 47% in men and between 7% and 38% in women. Up to 66% of some subtypes of cardiovascular (CV) disease such as fatal ischemic heart disease, hemorrhagic stroke and ischaemic stroke in this region are attributed to hypertension. 1 In China, despite a rapid increase in the prevalence of hypertension, only 24% of those with hypertension were reported to be aware of their condition in a 2002 survey. 2 In a multicentre, cross-sectional registration survey in China, it was observed that 30.6% of hypertensive patients overall achieved their blood pressure (BP) goal but the proportion was <15% in those with diabetes and renal dysfunction. 3 Hence, the introduction of formal BP-lowering strategies may have an immense impact in the Asian region. [4] [5] [6] Data from clinical trials suggest that >75% of patients with hypertension require combination therapy to achieve early BP goals. 7 Guidelines recommend the use of fixed-dose combinations to simplify treatment and to improve convenience and cost-effectiveness compared with other therapeutic options. 8 The additional BP reduction observed by combining drugs from two different classes is approximately five times greater than doubling the dose of one drug, 9 without an additive increase on the incidence of adverse events (AEs). 10 A single-pill combination of drugs with complementary action has been reported to reduce medication non-compliance by 24-26%. 11 Single-pill combinations help reduce pill burden, simplify treatment regimens and improve treatment adherence, thereby resulting in better BP control and longterm CV risk reduction compared with other therapeutic options. 12, 13 Use of an antihypertensive single-pill combination early in the treatment paradigm (including as firstline medication) may help to shrink the current gap between antihypertensive treatment use and BP goal achieved, and offer better therapeutic compliance. 14 Guidelines recommend a renin-angiotensin system inhibitor plus a calcium channel blocker as a rational combination due to their complementary mechanisms of action. 8, 15 A single-pill combination of an angiotensin II type 1 receptor blocker (ARB) plus a calcium channel blocker is emerging as perhaps the most suitable therapy for preventing CV disease, in addition to BP reduction, in patients with hypertension. 16 In China, a multicentre, cross-sectional registration survey of 5 086 patients with hypertension showed calcium channel blockers (56.6%) followed by ARBs (32.0%) to be the most commonly prescribed antihypertensive medications; >50% of patients were taking at least three antihypertensive drugs and single-pill combinations were prescribed as initial therapy in 12.7% of patients. 3 Telmisartan provides superior and consistent BP reductions over 24 h and beyond compared with other ARBs. 17 It is the first drug in the ARB class with a demonstrated CV risk reduction, similar to ramipril, in patients at high CV risk. 18 Telmisartan is the only ARB approved for the reduction of CV morbidity in patients with manifest atherothrombotic CV disease (history of coronary heart disease, stroke or peripheral artery disease) or diabetes mellitus with documented target organ damage. 19 The efficacy and favourable safety profile of telmisartan/ amlodipine single-pill combination in patients with hypertension has been shown in previous multinational studies. [20] [21] [22] [23] [24] The objective of the present study was to evaluate the efficacy and safety of the single-pill combination of telmisartan 80 mg (T80) plus amlodipine 5 mg (A5) in Asian patients with hypertension whose BP was not adequately controlled on A5 monotherapy.
Patients and methods Patients
Asian men and women, aged !18 years, with essential hypertension and BP not adequately controlled (defined as seated diastolic BP [DBP] !95 mmHg if on antihypertensive treatment, or !100 mmHg if treatment naı¨ve) were eligible for enrolment into the monotherapy screening phase of the trial.
Patients with secondary hypertension, any significant or unstable systemic disease, previous experience of symptoms characteristic of angioedema during treatment with angiotensin-converting enzyme inhibitors or ARBs, and women who were pregnant, breast-feeding or planning to become pregnant were excluded. In addition, mean seated systolic BP (SBP) !200 mmHg and/ or mean seated DBP !120 mmHg at screening or during the run-in period, or mean seated SBP !180 mmHg and/or mean seated DBP !120 mmHg at the end of the run-in period, and non-compliance with study medication (defined as <80% or >120%) during the run-in period were excluded.
The study was carried out in compliance with the protocol, the principles laid down in the Declaration of Helsinki, the International Conference on Harmonization (ICH) Harmonized Tripartite Guidelines for Good Clinical Practice and applicable regulatory requirements. The study protocol was reviewed by an independent ethics committee or institutional review board at each study site, and all patients provided written informed consent before entering the study.
Study design
This phase III, randomized, double-blind, double dummy, multinational, multicentre study was conducted between 28 July 2010 and 27 August 2011 at 16 investigative sites: 12 sites in China, two sites in Malaysia and two sites in the Philippines. The study consisted of a 6-week open-label monotherapy run-in period followed by an 8-week double-blind treatment period ( Figure 1 ). Enrolled patients were to stop their other treatments for hypertension, if any, before entering the run-in period. During the 6-week run-in period, patients received A5 once daily. Patients who responded to the initial monotherapy were withdrawn from the trial as screening failures. Those who did not reach the BP goal with A5 (defined as seated trough DBP !90 mmHg after 6 weeks), were randomly allocated in a 1 : 1 ratio to double-blind treatment with either T80/A5 or A5 (and placebo matching the alternative treatments) once daily for 8 weeks. Treatment allocation was determined according to the randomization code and each eligible patient was randomized by assigning the lowest treatment kit number available at the site to the patient. A complete block of randomization numbers was assigned to each centre.
The T80/A5 treatment was provided as single-pill combination tablets; A5 was provided as over-encapsulated capsules containing A5 tablets. Investigators counted the tablets for each patient at each visit postrandomization, and percentage medication compliance was calculated as the number of tablets actually taken since last count/ number of tablets that should have been taken in the same period Â100.
Efficacy assessments
Seated BP was measured at each visit using a standard validated and calibrated traditional manual cuff sphygmomanometer. A random zero sphygmomanometer with blinded measurements or automated device were not permitted. BP measurements were performed on the same arm and, if possible, by the same person at all study visits. At the screening visit, BP was measured in both arms. If the pressures differed by >10 mmHg, simultaneous readings were obtained in both arms, and the arm with the higher BP was used for subsequent measurements. The accuracy of BP measurements was increased by taking the mean of three consecutive measurements about 2 min apart. Figure 1 . Study design and patient flow diagram for patients enrolled into a randomized, double-blind study to evaluate the efficacy of a single-pill combination of telmisartan 80 mg plus amlodipine 5 mg compared with amlodipine 5 mg monotherapy. *Five patients in each treatment group were not included in the full analysis set, due to lack of primary endpoint information. Patients visited the study centre for efficacy and safety assessments after 4 weeks and 8 weeks during the double-blind treatment period. Baseline data for clinical characteristics and demographics were obtained at screening. For efficacy endpoints, the baseline value was the pre-dose measurement taken at randomization. Primary endpoint. The primary endpoint was the change from baseline of the mean seated trough DBP in: (a) the complete set of all randomized patients with hypertension who failed to respond adequately to treatment with A5 monotherapy; and (b) in the subset of Chinese patients who failed to respond adequately to treatment with A5 monotherapy.
Secondary endpoints. The key secondary endpoint was the change from baseline in seated trough SBP. Other secondary endpoints included: the proportion of patients achieving the BP goal (mean seated trough BP <140/90 mmHg); DBP goal attainment (mean seated trough DBP <90 mmHg); SBP goal attainment (mean seated trough SBP <140 mmHg); the proportion of patients achieving DBP response (mean seated trough BP <90 mmHg or DBP reduction !10 mmHg); the proportion of patients achieving SBP response (mean seated trough SBP <140 mmHg or SBP reduction !15 mmHg); the proportion of patients with optimal BP (<120/80 mmHg); the proportion of patients with normal BP (<130/ 85 mmHg and not optimal); the proportion of patients with high-normal BP (<140/ 90 mmHg and not optimal or normal); the proportion of patients with grade 1 (mild) hypertension, <160/<100 mmHg, but not high-normal; grade 2 hypertension (moderate), <180/<110 mmHg, but not grade 1 hypertension; grade 3 hypertension (severe): !180/!110 mmHg.
Efficacy endpoints were assessed after 4 and 8 weeks' treatment after the 6-week runin period or at last trough observation during the double-blind treatment period.
Safety assessments
Standard physical examinations, laboratory tests and 12-lead electrocardiogram assessments were carried out at screening, at randomization, and at the end of the study or at early withdrawal. Pulse rate and AEs were recorded at all visits.
Statistical analyses
To demonstrate the superiority of T80/A5 over A5 in the reduction from baseline in seated trough DBP of !3.5 mmHg, with a common standard variation of 8 mmHg (two-sided, a ¼ 0.05) at about 96% power, 152 evaluable patients per treatment group (n ¼ 304 in total) were needed. Assuming a 5% early withdrawal rate, a total of 320 patients were needed for a 1 : 1 randomization to the two treatment groups. Using the same assumptions, there was about 92% power to demonstrate the superiority of T80/A5 over A5 in the subset of !260 Chinese patients to be randomized.
For continuous variables, data were summarized using descriptive statistics. Treatment comparisons were performed using Student's t-test for independent samples. For categorical variables, data were summarized using frequency counts and percentages. Treatment comparisons were performed using 2 -test or Fisher's exact test, if appropriate. The primary and key secondary efficacy endpoints were compared between treatment groups using an analysis of covariance model including treatment, country and predose randomization baseline measurement as covariates. Other secondary efficacy endpoints were compared between treatment groups using Fisher's exact test. Safety endpoints were summarized. Last observation carried forward was used to impute missing data for the endpoints involving seated trough BP measurements (last trough observation carried forward). The remaining efficacy variables and all safety variables were analysed without substitution of missing values.
The run-in set included all patients who were treated during the run-in period. The full analysis set, which included all patients who took at least one dose of double-blind trial medication, and for whom a baseline measurement and at least one post-baseline trough efficacy measurement were available, was used for efficacy analysis. The treated set, which included all randomized patients who were dispensed double-blind study medication and who took at least one dose of investigational treatment, was used for safety analysis. All tests were conducted as two-tailed at the 5% level of significance. P-values from the treatment comparisons 0.05 were considered statistically significant. SAS software, version 9.2 (SAS Institute Inc., Cary, NC, USA) was used for all analyses.
Results Patients
A total of 405 patients were enrolled in the study: 381 entered the run-in period, 324 were randomized to double-blind treatment and 317 completed the treatment period (Figure 1 ). Fifty-seven patients from the run-in period were not randomized to double-blind treatment because they did not meet the entry criteria (i.e. DBP was <90 mmHg). The most frequent reasons for study discontinuation during the randomized treatment period were AEs and patient refusal to continue trial medication, each of which was reported in two patients in the A5 group and one patient in the T80/A5 group.
Demographic and baseline characteristics of the patients (obtained at screening) were similar in the two treatment groups (no between-group statistical analyses were performed on these data; Table 1 ). Most patients 276/314 (!87%) had received previous antihypertensive therapy. Mean SBP/ DBP was >150/>100 mmHg in the two treatment groups; none of the patients had DBP <90 mmHg, and less than a quarter of patients in each of the treatment groups had SBP <140 mmHg. Most patients were nonsmokers and did not consume alcohol. At baseline, >60% of patients in the A5 and T80/A5 groups had grade 1 hypertension (Table 2) .
Mean BP values at screening, the start of run-in, and randomization were balanced between the two treatment groups. At randomization, mean AE SE SBP was 146.27 AE 0.88 mmHg in the A5 group and 146.44 AE 0.98 mmHg in the T80/A5 group, and mean AE SE DBP was 97.84 AE 0.51 mmHg in the A5 group and 97.21 AE 0.44 mmHg in the T80/A5 group. Percentage medication compliance was 92.7% during the run-in period, and >99% during the randomized treatment period. During the run-in period, mean AE SD exposure was 43.77 AE 2.67 days. During the randomized period, for the treated set, the mean AE SD exposure was similar in the A5 group (58.93 AE 8.57 days; range 4-75 days) and in the T80/A5 group (59.66 AE 5.86 days; range 16-72 days; no between-group statistical analyses were performed on the exposure data).
The demographic and baseline characteristics of Chinese patients were consistent with those of the overall population and were similar in the two treatment groups. The demographic and baseline characteristics (obtained at screening) of the full analysis set were similar to those of the treated set and run-in set (data not shown).
Efficacy
Primary endpoint. Adjusted mean AE SE reduction in seated trough DBP from baseline to week 8 in the full analysis set was significantly greater in the T80/A5 group (À12.4 AE 0.95 mmHg) than in the A5 group (À10.2 AE 0.93 mmHg; P ¼ 0.007; Figure 2A) . Similar results were observed in the subset of Chinese patients (mean AE SE reduction in seated trough DBP: T80/A5 group, À10.77 AE 0.64 mmHg; A5 group, À8.85 AE 0.63 mmHg; P ¼ 0.034; Figure 2B ). Secondary endpoints. Adjusted mean AE SE reduction from baseline to week 8 in seated SBP (key secondary endpoint) was significantly greater in the T80/A5 group (À16.15 AE 1.33 mmHg) than in the A5 group (À11.66 AE 1.30 mmHg; P < 0.001). Similarly, in the subset of Chinese patients, mean AE SE reduction from baseline to week 8 in seated SBP was significantly greater in the T80/A5 group (À13.69 AE 0.88 mmHg) than in the A5 group (À9.38 AE 0.87 mmHg; P < 0.001).
The BP goal attainment rate (<140/ <90 mmHg) at week 8 was significantly higher in the T80/A5 group (64.5%; 95% confidence interval [CI] 56.4, 72.0) than in Table 1 . Demographic and baseline characteristics of the full analysis set of Asian patients enrolled in a randomized, double-blind study to evaluate the efficacy of a single-pill combination of telmisartan 80 mg plus amlodipine 5 mg (T80/A5) compared with amlodipine 5 mg monotherapy (A5). the A5 group (45.3%; 95% CI 37.4, 53.4; P ¼ 0.0007). The percentage of patients achieving the seated trough DBP goal (<90 mmHg) and seated trough SBP goal (<140 mmHg) at week 8 was also significantly higher in the T80/A5 group than in the A5 group (Figure 3 ). The response rates for DBP (<90 mmHg and/or reduction from baseline !10 mmHg) and SBP (<140 mmHg and/or reduction from baseline !15 mmHg) were significantly higher in the T80/A5 group compared with the A5 group at both week 4 and week 8 (Figure 4) . The percentage of patients whose BP was normalized was higher for each response category (optimal, normal or high-normal) in the T80/A5 group than in the A5 group at week 4 and week 8 ( Table 2 ). The percentages of patients with grade 1, 2 or 3 hypertension decreased from baseline in both treatment groups at week 4 and week 8, with larger decreases from baseline in the percentage of patients with grade 1 and grade 2 hypertension in the T80/A5 group than the A5 group (Table 2) .
Safety. During the run-in period, 26 of the 381 patients (6.8%) experienced an AE. The most frequently reported (those occurring in more than one patient) AEs were dizziness (n ¼ 9, 2.4%), headache (n ¼ 7, 1.8%) and cough (n ¼ 2, 0.5%). One patient died (sudden death) and one patient experienced a serious AE of cerebrovascular accident. Both were considered by an independent physician to be not related to study treatment. Treatment-related AEs occurred in 12 patients (3.1%): the most common (occurring in more than one patient) were headaches (n ¼ 7, 1.8%) and dizziness (n ¼ 5, 1.3%). Six patients (1.6%) discontinued due to AEs: dizziness was the most common reason (occurring in more than one patient) (n ¼ 4, 1%). During the randomized treatment period, similar percentages of patients in the two treatment groups reported AEs. The most frequently reported AEs (defined as those that occurred in at least two patients in at least one of the treatment groups) were hyperlipidaemia, dyslipidaemia, nasopharyngitis, upper respiratory tract infection, diabetes mellitus, hyperuricaemia, dizziness, headache, blood glucose increase and the presence of protein in urine (Table 3 ). Most AEs were of mild intensity. Treatmentrelated AEs occurred in four (2.4%) patients in the A5 group and in three (1.9%) patients in the T80/A5 group; headache (two patients [1.2%] in the A5 group, one patient [0.6%] in the T80/A5 group), peripheral oedema (one patient in each group, 0.6%), cough (one patient [0.3%] in the A5 group, none in the T80/A5 group) and epistaxis (none in the A5 group, one patient [0.6%] in the T80/A5 group).
There were no reports of death or serious AEs during the randomized treatment period. Discontinuation due to AEs (all considered as 'significant AEs' according to ICH E3 25 ) occurred for two patients (1.2%) in the A5 group (cough [n ¼ 1] and headache [n ¼ 1]) and one patient (0.6%) in the T80/ A5 mg group (epistaxis). One patient (0.6%) in the T80/A5 mg group had a significant AE of hypokalaemia, which did not result in study discontinuation.
There were no clinically important differences in laboratory parameters between the two treatment groups during the randomized treatment period. Changes from baseline to the end of treatment in pulse rate were small and similar in both treatment groups.
Discussion
In the present trial, as expected, patients who were randomized to A5 monotherapy continued to have a benefit on BP control during the 8 weeks' randomized treatment period, even though they did not respond adequately to the 6-week open-label treatment. In non-responder trials, further BP reduction during the double-blind treatment phase in those patients who continue to receive the same monotherapy as in the runin phase is a common observation. 22, 23, [26] [27] [28] This is due not only to the placebo effect but also to the regression-to-the-mean phenomenon. The crucial factor in such trials is to demonstrate a statistically significant and clinically relevant additional BP reduction in response to the combination therapy in patients who did not respond adequately to standard therapeutic doses of the monotherapy. 29 In the present study, the T80/A5 singlepill combination was significantly more effective than continued A5 monotherapy in further lowering the BP in Asian patients with hypertension whose BP was not adequately controlled during 6 weeks of A5 monotherapy. The T80/A5 single-pill combination was also significantly more effective than A5 monotherapy in a subset of Chinese patients. T80/A5 single-pill combination treatment resulted in significantly higher adjusted mean differences between baseline and week 8 in DBP and SBP than A5 monotherapy. The BP goal attainment rate and response rates at the end of 8 weeks were significantly higher in the T80/A5 single-pill combination group than in the A5 group.
The results of the present study are consistent with those observed in previous international studies conducted in patients with hypertension not controlled on amlodipine monotherapy. In those studies, telmisartan/amlodipine single-pill combination has been shown to result in superior BP reduction and achievement of BP goal and response rates. [20] [21] [22] [23] The telmisartan/ amlodipine combination also provides superior 24-h BP lowering compared with either drug administered as monotherapy in patients with mild to moderate hypertension. 24 The efficacy and favourable safety profile of the ARB/amlodipine combination has been shown in a wide variety of patients, including those with severe hypertension, those at added risk of CV events [30] [31] [32] [33] [34] [35] [36] [37] and in the elderly. 38 The T80/A10 combination resulted in a greater decrease in BP, and in higher BP goal rates, compared with amlodipine monotherapy in patients with diabetes and hypertension. 35 The telmisartan/amlodipine combination was also shown to be well tolerated, to reduce BP effectively, and to enable the majority of hypertensive patients with obesity, diabetes or the metabolic syndrome to achieve target BP in a post hoc subgroup analysis of data from 13 clinical trials. 36 Response to antihypertensive treatment may vary among different ethnic groups. In a pre-specified analysis of the BP-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA), important differences in BP responses were observed among ethnic groups with regard to treatment with atenolol (as first-line) and perindopril (as an add-on to amlodipine), while response to amlodipine as first-line, and thiazide diuretics as an add-on, did not vary. 39 In the present study, there were no differences observed between the overall Asian population and the Chinese subgroup for any measure.
Overall, double-blind treatment with either A5 or T80/A5 for 8 weeks was well tolerated in the present study. The safety and tolerability data obtained were consistent with the known profiles of telmisartan and amlodipine, and no clinically important differences were noted in safety and tolerability between the A5 group and the T80/A5 group in the 8-week double-blind, randomized treatment period. In previous studies, telmisartan/amlodipine single-pill combination treatment was associated with a lower incidence of peripheral oedema than amlodipine monotherapy. [20] [21] [22] [23] In the present study, the incidence of peripheral oedema was low, and was reported in one patient in each group. The present study included only Chinese, Malaysian and Philippine patients, which may limit the applicability of the findings to patients from other Asian countries. In addition, the controlled nature of the study limits generalization of the results to those categories of patients who were excluded from the study.
In conclusion, 8 weeks of treatment with T80/A5 single-pill combination provided superior BP-lowering efficacy compared with A5 monotherapy for Asian patients whose BP was not controlled with A5 monotherapy. Results were consistent in the subset of Chinese patients. The safety and tolerability profile of T80/A5 single-pill combination is comparable to that of A5 monotherapy and consistent with that reported in previous studies. Table 3 . Adverse events (AEs) that occurred in at least two patients in either treatment group in the randomized treatment period, in those enrolled in a randomized, double-blind study to evaluate the efficacy of a single-pill combination of telmisartan 80 mg plus amlodipine 5 mg (T80/A5) compared with amlodipine 5 mg monotherapy (A5). 
